ORIC PHARMACEUTICALS INC (ORIC) Stock Price, Quote, News and Overview
NASDAQ:ORIC - Nasdaq - US68622P1093 - Common Stock - Currency: USD
ORIC Quote, Performance and Key Statistics
ORIC PHARMACEUTICALS INC
NASDAQ:ORIC (2/11/2025, 5:59:18 PM)
After market: 9.9 +0.05 (+0.51%)9.85
-1.38 (-12.29%)
The current stock price of ORIC is 9.85 USD. In the past month the price increased by 14.53%. In the past year, price decreased by -12.44%.
ORIC Latest News and Analysis
Tuesday's session: gap up and gap down stocks
Let's have a look at the gap up and gap down stocks in today's session.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company...
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company...
ORIC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.96 | 338.99B | ||
| AMGN | AMGEN INC | 14.97 | 159.46B | ||
| GILD | GILEAD SCIENCES INC | 21.7 | 119.82B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1569.72 | 117.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.58 | 73.13B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.69B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.45B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.57B | ||
| NTRA | NATERA INC | N/A | 22.41B | ||
| BIIB | BIOGEN INC | 8.54 | 20.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.77B |
Related stock screener links
About ORIC
Company Profile
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 112 full-time employees. The company went IPO on 2020-04-24. The company is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Company Info
ORIC PHARMACEUTICALS INC
240 E. Grand Ave, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Jacob M. Chacko
Employees: 112
Company Website: http://oricpharma.com/
Investor Relations: https://investors.oricpharma.com/
Phone: 16503885600
ORIC FAQ
What is the stock price of ORIC?
The current stock price of ORIC is 9.85 USD.
What is the symbol for ORIC PHARMACEUTICALS INC stock?
The exchange symbol of ORIC PHARMACEUTICALS INC is ORIC and it is listed on the Nasdaq exchange.
On which exchange is ORIC stock listed?
ORIC stock is listed on the Nasdaq exchange.
Is ORIC a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ORIC, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ORIC.
Does ORIC stock pay dividends?
ORIC does not pay a dividend.
What is the Price/Earnings (PE) ratio of ORIC?
ORIC does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.8).
What is the Short Interest ratio of ORIC stock?
The outstanding short interest for ORIC is 17.62% of its float.
ORIC Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ORIC. When comparing the yearly performance of all stocks, ORIC turns out to be only a medium performer in the overall market: it outperformed 47.02% of all stocks.
ORIC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORIC. ORIC has a great financial health rating, but its profitability evaluates not so good.
ORIC Financial Highlights
Over the last trailing twelve months ORIC reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 9.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.68% | ||
| ROE | -43.75% | ||
| Debt/Equity | 0 |
ORIC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to ORIC. The Buy consensus is the average rating of analysts ratings from 18 analysts.